Sign in
Taking people in United StatesPhase 3

HBS-301 for daytime sleepiness and related symptoms in adults with narcolepsy

Tests HBS-301 against placebo in adults with narcolepsy.

Key facts

Who runs it
Harmony Biosciences Management, Inc.
Where
Abington, Ardmore, Atlanta, Austin, Birmingham, Boulder, Charleston, Chesterfield, Cincinnati, Cleveland, Colorado Springs, Columbia, Dallas, Danville, Denver, East Providence, Fort Wayne, Gastonia, Glenview, Huntersville, Kansas City, Kenner, Lancaster, Los Angeles, Macon, Madison, McKinney, Miami, Middletown, Mobile, Morgantown, Nashville, New Hyde Park, Novi, Peoria, Pittsburgh, Redwood City, Rincon, San Antonio, San Francisco, San Ramon, Southfield, Spokane, Sterling Heights, Stockbridge, Sugar Land, Williamsburg, Winter Park, and Wyomissing, United StatesSee the 52 sitesAlso in 7 other countries, 24 sites
Registry title
A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy
Status
Recruiting
Phase
Phase 3
People taking part
258 people, planned
Started
4 Jun 2026
Expected to end
Nov 2027
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • HBS-301
  • Placebo
Record updated
13 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with narcolepsy type 1 or type 2 who have excessive daytime sleepiness. It tests HBS-301 against a placebo (dummy tablet).

Age
18 years and older
Sex
All sexes
Disease stage
Narcolepsy type 1 (NT1) or type 2 (NT2), diagnosed by ICSD-3 or ICSD-3-TR within the last 10 years, with excessive daytime sleepiness (EDS).
Earlier treatment
Allowed long-term medicines or supplements, including some antidepressants or wake-promoting drugs, must be at a stable dose for at least 3 months before screening. People cannot use treatments affecting daytime sleepiness only when needed, such as oxybates, stimulants, modafinil or armodafinil. No pitolisant within 5 half-lives before screening.

Main reasons for not taking part

  • Too much sleepiness caused by another medical disorder
  • Mental illness, including depression, not well controlled for at least 3 months, or any history of bipolar disorder or psychosis
  • Acute or chronic liver disease, or past moderate or severe liver impairment
  • Kidney function (eGFR) below 60 mL/min
  • Known long QT syndrome or serious heart tracing (ECG) problems

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Has a current documented diagnosis of NT1 or NT2 per the International Classification of Sleep Disorders, Third Edition (ICSD-3) or the ICSD-3 Text Revision (ICSD-3-TR) within the last 10 years
  • Has EDS
  • If taking a permitted chronic concomitant medication or supplement, including nonprohibited antidepressants or wake-promoting agents, must be on a stable dose for at least 3 months prior to Screening and agree to continue at that stable dose for the Double-blind Treatment Period of the study. As needed (PRN) use of any treatment that could affect daytime sleepiness (including but not limited to oxybates, stimulants, modafinil, and armodafinil) is not permitted

Who cannot take part

  • Has a history of pitolisant use within 5 half-lives prior to Screening
  • Has a primary diagnosis of psychiatric illness, including depression, that is not well controlled (i.e., symptoms and medications have not been stable for at least 3 months prior to Screening)
  • Has hypersomnia due to another medical disorder
  • Has any history of bipolar disorder or psychosis
  • Has acute or chronic liver disease or a history of moderate or severe hepatic impairment
  • Has a body surface area-corrected estimated glomerular filtration rate (eGFR) <60 mL/min
  • Has a known history of long QT syndrome or serious abnormality of the electrocardiogram (ECG)

Where in United States

Also in 7 other countries, 24 sites

  • Abington Neurological AssociatesAbington, United StatesContact: Rachel GrossmanTaking people
  • Neurology CareArdmore, United StatesContact: Maaz GhaniNot yet recruiting
  • NeuroTrials Research IncAtlanta, United StatesContact: Shriya ParekhTaking people
  • Aayus ResearchAustin, United StatesContact: Maria-Fernanda GameroTaking people
  • Sleep Disorders Center of AlabamaBirmingham, United StatesContact: Joseph WrightTaking people
  • Alpine Clinical Research Center, IncBoulder, United StatesContact: Federica BrescianiTaking people
  • Lowcountry Lung and Critical Care, PACharleston, United StatesContact: Courtney ArnoldTaking people
  • Medical University of South CarolinaCharleston, United StatesContact: Brooke CameronTaking people
  • St. Lukes Sleep Medicine and Research CenterChesterfield, United StatesContact: Kimberly Allen-BowzerTaking people
  • Intrepid Research, LLCCincinnati, United StatesContact: Tiffany SchiraTaking people
  • The Cleveland Clinic FoundationCleveland, United StatesContact: Alex PiczerNot yet recruiting
  • Delta Waves LLCColorado Springs, United StatesContact: Emma GallagherTaking people
  • Bogan Sleep Consultants, LLCColumbia, United StatesContact: Lorraine PottsTaking people
  • Southwest Family MedicineDallas, United StatesContact: Safia ShaikhTaking people
  • Geisinger Medical CenterDanville, United StatesContact: Cheryl PysherNot yet recruiting
  • Research Carolina Elite LLCDenver, United StatesContact: Heather Micun, RMA, CRCTaking people
  • Infinity Medical Research, Inc.East Providence, United StatesContact: Patricia MelloNot yet recruiting
  • Fort Wayne Neurological CenterFort Wayne, United StatesContact: James StevensTaking people
  • Clinical Research of GastoniaGastonia, United StatesContact: Melissa LanhamTaking people
  • Northshore University HealthSystemGlenview, United StatesContact: Anna PhamNot yet recruiting
  • Stern Research PartnersHuntersville, United StatesContact: Felix KurniawanTaking people
  • University of Kansas Hospital Main CampusKansas City, United StatesContact: Whitney TheisNot yet recruiting
  • Latnus Clinical ResearchKenner, United StatesContact: Suhas MadaboinaTaking people
  • West Coast Pulmonary & Sleep Disorders CenterLancaster, United StatesContact: Stephanie NavaTaking people
  • Santa Monica Clinical TrialsLos Angeles, United StatesContact: Samantha MontanezTaking people
  • Sleep Practitioners, LLCMacon, United StatesContact: Noelle WilliamsTaking people
  • University of Wisconsin - MadisonMadison, United StatesContact: Ahmad AllenTaking people
  • Metroplex Pulmonary and Sleep CenterMcKinney, United StatesContact: Rupa KrishnaTaking people
  • PharmaDev Clinical Research Institute, LLCMiami, United StatesContact: Rolando RodriguezTaking people
  • Patient First MDMiddletown, United StatesContact: Avraham TuvyTaking people
  • Springhill Medical CenterMobile, United StatesContact: Kennedy GreenTaking people
  • West Virginia University HospitalMorgantown, United StatesContact: Lauren ChaseNot yet recruiting
  • K2 Medical Research - NashvilleNashville, United StatesContact: Francesca McKayTaking people
  • Northwell Health Physician PartnersNew Hyde Park, United StatesContact: Kirendra PasramTaking people
  • Henry Ford Medical CenterNovi, United StatesContact: Michaela MogleTaking people
  • OSF St Francis Medical CenterPeoria, United StatesContact: Kimberly HartwigNot yet recruiting
  • Phoenix Medical Group, PCPeoria, United StatesContact: Daniel KasenovichTaking people
  • University of PittsburghPittsburgh, United StatesContact: Steve SwangerNot yet recruiting
  • Stanford Center for Sleep Sciences and MedicineRedwood City, United StatesContact: Sara LombaTaking people
  • Southeast Lung Associates ResearchRincon, United StatesContact: Lisa RodnickiTaking people
  • HASresearchSan Antonio, United StatesContact: Kimberly RosalesTaking people
  • Sleep Therapy Research CenterSan Antonio, United StatesContact: Erin MarshallTaking people
  • University of California San FranciscoSan Francisco, United StatesContact: Kyra PowersTaking people
  • Trial Site SolutionsSan Ramon, United StatesContact: Phil StraussTaking people
  • Revive Research Institute, IncSouthfield, United StatesContact: Abhishek DhillonTaking people
  • Sleep and Performance Research CenterSpokane, United StatesContact: Olivia BrooksTaking people
  • Clinical Neurophysiology ServicesSterling Heights, United StatesContact: Jessica AustinTaking people
  • Clinical Research Institute of Georgia LLCStockbridge, United StatesContact: Beverley JenkinsTaking people
  • Tricoastal Narcolepsy and Sleep Disorders CenterSugar Land, United StatesContact: Natalia DubockTaking people
  • TPMG Clinical ResearchWilliamsburg, United StatesContact: Michelle ManuelNo longer taking part
  • Florida Pediatric Sleep Disorders InstituteWinter Park, United StatesContact: Heidi PatenaudeTaking people
  • Berks Schuylkill Respiratory SpecialistsWyomissing, United StatesContact: Lisa HillTaking people

About the trial

What the trial wants to find out

This is a Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled clinical study to assess the efficacy and safety of HBS-301 in treating excessive daytime sleepiness (EDS), cataplexy, sleepiness/wakefulness, and fatigue in adult participants (ages ≥18 years) with narcolepsy.

The 3 groups in the trial

  • Double-Blind Treatment Period HBS-301Treatment being tested

    HBS-301 tablets administered once daily in the morning upon wakening

    Treatment: HBS-301

  • Double-blind Treatment Period PlaceboPlacebo, for comparison

    Matching placebo tablets administered once daily in the morning upon wakening

    Treatment: Placebo

  • Open-Label Extension Period HBS-301Treatment being tested

    HBS-301 tablets administered once daily in the morning upon wakening

    Treatment: HBS-301

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy Followed by an Open-label Extension
Plain-language title
HBS-301 for daytime sleepiness and related symptoms in adults with narcolepsyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
13 November 2026